2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Molecular Testing, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3603 Salvage outcomes and strategies in hepatosplenic T-cell lymphoma: A multicenter analysis

Varun Iyengar, MD, Andriy Derkach, PhD2, Vaishali Gautam, BS3, Luis Malpica, MD4, Parastoo B. Dahi, MD5, Zachary Epstein-Peterson, MD6, Paola Ghione, MD, MS7, Chitra Hosing, MD8, Alison Moskowitz, MD9, Miguel-Angel Perales, MD10, Rishab Prakash, BS11, Craig Sauter, MD12, Michael Scordo, MD13, Gunjan L. Shah, MD, MS14, Moneeza Walji, MD15, Mariko Yabe, MD, PhD16, Jasmine Zain, M.D.17, Swaminathan P. Iyer, MD18, Steven Horwitz, M.D.19, Robert Stuver, MD20
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 MD Anderson Cancer Center, Houston, United States
4 MD Anderson Cancer Center, Houston, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 MD Anderson Cancer Center, Houston, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 MD Anderson Cancer Center, Houston, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 MD Anderson Cancer Center, Houston, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction:
Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive malignancy for which prospective studies are lacking. Guidelines rely on small retrospective series and recommend non-CHOP–based induction followed by consolidative allogeneic hematopoietic stem cell transplantation (alloHCT). However, HSTCL is often refractory to chemotherapy and progresses rapidly with an urgent need for salvage; management in these relapsed/refractory (R/R) settings is poorly defined given the underrepresentation of HSTCL in clinical trials. To address this gap, we evaluated contemporary treatment patterns at two academic centers to refine our understanding of salvage strategies and outcomes.

Methods:
This retrospective cohort study included HSTCL patients (pts) treated at Memorial Sloan Kettering and MD Anderson Cancer Center from 2010–2025. Pathology was confirmed at each site. Pts were eligible for frontline analyses if they were followed from diagnosis or referred within 6 months of starting treatment; analysis was adjusted for referral bias using left truncation. Frontline regimens were categorized as intensive (e.g., ICE, EPOCH) or less intensive (e.g., CHOP). Salvage therapies were classified by mechanism of action. Primary endpoints were progression-free survival (PFS) following frontline (1L), second-line (2L), and third-line (3L) therapy. Secondary endpoints included overall response rate (ORR), complete response rate (CRR), and overall survival (OS). For salvage treatments, we reported response as documented in the medical record; however, given the limitations in retrospective response assessments and lack of uniform response criteria for HSTCL (Iyer et al., Blood 2025), we also report the proportion of pts who proceeded to alloHCT following salvage as a measure of disease control sufficient to permit consolidation.

Results:
We identified 56 pts that met inclusion criteria, 42 of whom were eligible for frontline analyses (N=36 referred at diagnosis). Median age at diagnosis was 39 years (range: 12-75) with male predominance (75%). Most pts received intensive induction therapy (82%).

With a median (m) follow-up of 82 months, mPFS and mOS were 5.2 (95% CI, 4.2–not reached [NR]) and 27.1 months (95% CI, 12.6–NR), respectively. Estimated 1- and 5-year PFS were 45% (95% CI, 32–62%) and 34% (95% CI, 22–52%), and 1- and 5-year OS were 66% (95% CI, 53–82%) and 40% (95% CI, 27–59%). Receipt of alloHCT following 1L therapy (N=21) was associated with improved survival (5-year PFS: 60% [95% CI, 39–92%], HR 0.3 [95% CI, 0.1–0.8], p=0.02; 5-year OS: 67% [95% CI, 47–96%], HR 0.2 [95% CI, 0.1–0.5], p<0.01).

A total of 29 pts with R/R disease received salvage treatment. 2L regimens included chemotherapy (N=18; predominantly ICE/IVAC [N=8]), histone deacetylase inhibitors (HDACi; N=4), JAK/STAT inhibitors (N=4), HDAC/PI3Ki combinations (N=2), and alemtuzumab (N=1). The documented ORR and CRR were 52% and 19%, respectively, though only 10% (N=3) of pts proceeded to alloHCT. 2L regimens that facilitated transplant were ICE (N=1), EPOCH (N=1), and ruxolitinib (N=1). mPFS and mOS from the start of 2L therapy were 1.9 months (95% CI, 1.0–3.5) and 6.3 months (95% CI, 2.7–12.5), respectively; 1-year PFS and OS were 10% (95% CI, 3–30%) and 32% (95% CI, 18–57%). Among the three pts who proceeded to alloHCT, one relapsed at 2 months, one died at 18 months (unrelated to HSTCL), and one remains in remission at 7 years.

Thirteen pts received 3L treatment. Regimens were a mix of chemotherapy (N=6) and novel agents (e.g., HDAC/PI3Ki combination [2], JAK/STATi [2], CD94 antibody [1], MDM2/MDMX inhibitor [1], HDAC/PI3K dual inhibitor [1]). The ORR/CRR were 54%/23%, and 23% (N=3) of pts proceeded to alloHCT. 3L regimens that facilitated transplant were ICE/IVAC (N=2) and an HDAC/PI3Ki combination (N=1). mPFS and mOS from the start of 3L therapy were 1.7 months (95% CI, 1.0–NR) and 9.5 months (95% CI, 3.5–NR); 1-year PFS and OS were 8% (95% CI, 1–54%) and 25% (95% CI, 9–67%). Among the three pts who proceeded to alloHCT, two relapsed (at 6 and 8 months, respectively), while the remaining pt died at 10 months (cause unknown).

Conclusion
In this multicenter cohort, salvage treatments for HSTCL induced responses, though successful bridging to alloHCT was uncommon and achieved primarily with chemotherapy-based regimens. This report sets a benchmark against which to compare future agents and highlights the pressing need for more effective and durable therapies.

Varun Iyengar, MD: No relevant conflicts of interest to declare.